Literature DB >> 2991921

Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3.

J A MacLaughlin, W Gange, D Taylor, E Smith, M F Holick.   

Abstract

We examined the responsiveness of cultured dermal fibroblasts from biopsies of uninvolved and involved areas of skin from six patients with psoriasis to the cell-proliferation-inhibition activity of 1,25-dihydroxyvitamin D3 (1,25-(OH)2-D3). Cultured fibroblasts from age-matched controls responded to 1,25-(OH)2-D3 (at 0.01, 1, 10, and 100 microM) in a dose-dependent fashion, whereas cultured psoriatic fibroblasts from involved or uninvolved skin showed no inhibition of proliferation when exposed to 0.01 or 1 microM of 1,25-(OH)2-D3. However, 1,25-(OH)2-D3 did inhibit proliferation of cultured psoriatic fibroblasts when the concentrations were increased to 10 and 100 microM. An analysis of the 1,25-(OH)2-D3 receptors in cultured psoriatic fibroblasts from uninvolved skin revealed that the Kd, nmax, and sedimentation coefficient were identical to the receptors found in the fibroblasts from age-matched controls. Therefore, cultured psoriatic fibroblasts from involved and uninvolved skin have a partial resistance to 1,25-(OH)2-D3, suggesting that there may be a biochemical defect that is inherent in the dermal fibroblasts of psoriatic patients. Recognition of this defect may provide a new approach for the evaluation of the cause and treatment of this disfiguring skin disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991921      PMCID: PMC390578          DOI: 10.1073/pnas.82.16.5409

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Fractionation of glycosaminoglycans from psoriatic skin.

Authors:  R Fleischmajer; N Blumenkrantz
Journal:  J Invest Dermatol       Date:  1970-10       Impact factor: 8.551

3.  Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid.

Authors:  W E Stumpf; M Sar; F A Reid; Y Tanaka; H F DeLuca
Journal:  Science       Date:  1979-12-07       Impact factor: 47.728

4.  Vitamin D metabolites change the phenotype of monoblastic U937 cells.

Authors:  R C Dodd; M S Cohen; S L Newman; T K Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60).

Authors:  H Tanaka; E Abe; C Miyaura; T Kuribayashi; K Konno; Y Nishii; T Suda
Journal:  Biochem J       Date:  1982-06-15       Impact factor: 3.857

6.  Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3.

Authors:  D Feldman; T Chen; C Cone; M Hirst; S Shani; A Benderli; Z Hochberg
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

7.  Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3.

Authors:  J Hosomi; J Hosoi; E Abe; T Suda; T Kuroki
Journal:  Endocrinology       Date:  1983-12       Impact factor: 4.736

8.  Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3.

Authors:  J E Griffin; J E Zerwekh
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

9.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.

Authors:  E Abe; C Miyaura; H Sakagami; M Takeda; K Konno; T Yamazaki; S Yoshiki; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

10.  Nuclear uptake of 1,25-dihydroxy[3H]cholecalciferol in dispersed fibroblasts cultured from normal human skin.

Authors:  C Eil; S J Marx
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

View more
  20 in total

1.  Treating psoriasis with calcipotriol.

Authors:  P C Newbold
Journal:  BMJ       Date:  1992-10-10

2.  Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.

Authors:  S Takamoto; T Onishi; S Morimoto; S Imanaka; S Yukawa; T Kozuka; Y Kitano; Y Seino; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-12       Impact factor: 4.333

3.  The mRNA expression of the human 1,25-dihydroxyvitamin D3 receptor and the c-myc protooncogene in cultured human keratinocytes.

Authors:  N M Hanafin; K S Persons; M F Holick
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-03       Impact factor: 2.416

Review 4.  Resurgence of vitamin D: Old wine in new bottle.

Authors:  Raju Vaishya; Vipul Vijay; Amit Kumar Agarwal; Jabed Jahangir
Journal:  J Clin Orthop Trauma       Date:  2015-03-26

5.  Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells.

Authors:  J D Fraser; P A Price
Journal:  Calcif Tissue Int       Date:  1990-04       Impact factor: 4.333

6.  Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.

Authors:  S Morimoto; K Yoshikawa; T Kozuka; Y Kitano; S Imanaka; K Fukuo; E Koh; T Onishi; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

7.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

Review 8.  Vitamin D deficiency in early life and the potential programming of cardiovascular disease in adulthood.

Authors:  Oksan Gezmish; Mary Jane Black
Journal:  J Cardiovasc Transl Res       Date:  2013-05-30       Impact factor: 4.132

Review 9.  Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.

Authors:  Jörg Reichrath; Christos C Zouboulis; Thomas Vogt; Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 10.  Vitamin D3 and skin diseases.

Authors:  K Kragballe
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.